Amy Lin, MD
Ophthalmology · Salt Lake City, UTNPI 1104045566
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (48.7%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. 25 manufacturers reported payments, led by Tarsus Pharmaceuticals, Inc. at 30.0% of the total. Among ophthalmology clinicians in UT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 119 payments — averaging $127.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tarsus Pharmaceuticals, Inc.$5K
- Dompe US, Inc.$3K
- Kala Pharmaceuticals, Inc.$2K
- Eyevance Pharmaceuticals LLC$1K
- Oyster Point Pharma, Inc.$866
- Lensar, Inc.$650
- plus $3K from 19 others
What the payments were for
- Consulting fees$6,05040%
- Speaking & faculty fees$1,65011%
- Food & beverage$7,39549%
- Education$801%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Tarsus Pharmaceuticals, Inc. | 12 | $4,552 |
| Dompe US, Inc. | 21 | $3,025 |
| Kala Pharmaceuticals, Inc. | 4 | $1,638 |
| Eyevance Pharmaceuticals LLC | 2 | $1,287 |
| Oyster Point Pharma, Inc. | 24 | $866 |
| Lensar, Inc. | 1 | $650 |
| Sun Pharmaceutical Industries Inc. | 8 | $461 |
| Novartis | 8 | $429 |
| Alcon | 5 | $373 |
| Shire North American Group Inc | 4 | $292 |
| AbbVie(2 entities) | 4 | $252 |
| Mallinckrodt Enterprises LLC | 2 | $235 |
| Biotissue Holdings Inc. | 2 | $132 |
| Astellas Pharma Global Development | 1 | $126 |
| Mallinckrodt Hospital Products Inc. | 2 | $124 |
| Bausch & Lomb Americas Inc. | 1 | $109 |
| Glaukos Corporation | 3 | $103 |
| Aerie Pharmaceuticals, Inc. | 1 | $102 |
| Amgen(2 entities) | 2 | $88 |
| Thea Pharma Inc. | 4 | $80 |
| Carl Zeiss Meditec, Inc. | 2 | $79 |
| Carl Zeiss Meditec USA, Inc. | 3 | $73 |
| Sight Sciences, Inc. | 1 | $37 |
| Ocular Therapeutix, Inc. | 1 | $36 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $26 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,175 in reported general payments places this provider in the 90th percentile of 191 ophthalmology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 131 | $120,425 |
| XiidraLifitegrast | 68 | $66,129 |
| Cyclosporine | 48 | $27,540 |
| Prednisolone Acetate | 296 | $11,824 |
| Ketorolac Tromethamine | 115 | $7,518 |
| Fluorometholone | 80 | $6,257 |
| Doxycycline Hyclate | 184 | $5,227 |
| ValacyclovirValacyclovir Hcl | 68 | $4,155 |
| Loteprednol Etabonate | 13 | $1,667 |
| ErythromycinErythromycin Base | 98 | $1,569 |
| MoxifloxacinMoxifloxacin Hcl | 30 | $751 |
| Ofloxacin | 24 | $663 |
| Latanoprost | 40 | $518 |
| Acyclovir | 32 | $351 |
| Azithromycin | 14 | $238 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis | $252 | $120,425131 claims |
| Bausch & Lomb Americas Inc.Xiidra | $109 | $66,12968 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $26 | $1,66713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 191 ophthalmology providers in Utah.
Other ophthalmology in Salt Lake City
- Iqbal AhmedSalt Lake City$895K
- Robert CionniSalt Lake City$161K
- Zachary ZavodniSalt Lake City$51K
- Majid MoshirfarSalt Lake City$44K
- Marc Steffen Schmitz-ValckenbergSalt Lake City$43K
- Rachel SimpsonSalt Lake City$39K
- Austin NakatsukaSalt Lake City$27K
- Douglas MarxSalt Lake City$22K
- Akbar ShakoorSalt Lake City$18K
- Craig ChayaSalt Lake City$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.